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Abstract 
Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been 
contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade 
and their expected outcomes with regard to Candida and Aspergillus infections in non‑neutropenic patients in the ICU 
setting.
Methods: A systematic review of the medical literature taking account of national and international guidelines and 
expert opinion.
Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approxi‑
mately 80% of IFIs are due to Candida spp. and 0.3–19% to Aspergillus spp. Recent observations emphasize the 
necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in 
susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality 
endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis 
of unknown cause, and positive Candida serum biomarkers [β‑1 → 3‑d‑glucan (BDG) and Candida albicans germ tube 
antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically 
address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge 
of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding inva‑
sive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza 
outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment.
Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies 
described in this research agenda should provide a template and set priorities for the clinical investigations that need 
to be performed.
Keywords: Candida, Aspergillus, Antifungals, Echinocandins, Fluconazole, Beta‑d‑glucan
Introduction
Invasive fungal infections (IFI) in critically ill patients are 
associated with considerable morbidity and mortality. 
This research agenda on IFI focuses on the more fre-
quent diseases, namely invasive candidiasis and invasive 
aspergillosis in non-neutropenic patients, but not on the 
so-called ultra-orphan fungal infections that may be as 
rare as less than 1 in 1  million population, e.g., mucor-
mycosis or trichosporonosis [1]. This article aims to 
highlight open questions and gaps in our knowledge and 
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understanding of epidemiology, risk factors, use of diag-
nostic tools, and antifungal compounds.
The critically ill patients treated today are a very het-
erogeneous group. This is why the authors of this article 
represent microbiology, intensive care, and clinical infec-
tious disease experts with views from Asia, Europe, and 
North America.
It was a major step forward that an international con-
sensus was established on the definitions of what con-
stitutes invasive fungal disease [2]. A common set of 
definitions allows comparison of results between studies 
to a certain extent, but even the definitions continue to 
evolve [3].
Treatment delays in critically ill patients negatively 
impact on outcomes. Invasive fungal infections are no 
exceptions to this rule. Thus the field moves towards 
earlier diagnosis followed by earlier treatment. The early 
strategic option obviously is prophylaxis, which has been 
proven successful in other clinical settings [4]. To avoid 
overtreatment in a large group of critically ill patients, 
any prophylactic approach needs a population at suffi-
ciently high risk, but currently it is unclear how to select 
such appropriate target groups.
Whether superiority of a certain treatment or strategy 
can be proven at all may depend on the clinical endpoint 
chosen. While echinocandins appear superior to azoles 
in terms of treatment success [5], it is much more chal-
lenging to improve survival rates by applying a single 
diagnostic tool or treatment decision. The diverse and 
complex problems that the individual critically ill patient 
at risk for IFI may face could easily mean several “com-
peting” life-threatening conditions at the same time. 
Thus, single interventions proven to save lives in a rand-
omized comparison are rare findings.
In critically ill patients we do not expect the next 
advance to come from a single pivotal drug trial, but 
rather from strategic trials integrating genetics profile 
of host and pathogen, diagnostic tools, antifungal treat-
ment, and therapeutic drug monitoring (TDM). Nothing 
less than individualized treatment may advance the field. 
Unfortunately, no such clinical trial has succeeded yet.
Methods
A systematic review for this project was conducted with 
a timeline from 2006 through 2016. Two authors of each 
of the two sections (Candida and Aspergillus) searched 
PubMed using the terms Candida, Aspergillus, antifun-
gal therapy, and critically ill patients. Searches were com-
pleted in February 2017. One author (MB) also manually 
screened reference lists of articles selected for inclusion 
to identify additional studies. The selection of articles 
and topics for inclusion in this research agenda from the 
systematic review were based on their likely importance 
for yielding clinically important practice changes over the 
next decade as determined by the writing committee.
What is the current standard of care for delivering the best 
possible critical care in the field?
Invasive candidiasis
Invasive fungal infections (IFIs) are an increasingly fre-
quent cause of severe infections with between 30% and 
40% of IFIs episodes occurring in critically ill patients [6]. 
Approximately 80% of IFIs are due to Candida species. 
In a worldwide ICU prevalence study, Candida was the 
third most frequently isolated microorganism accounting 
for 17% of all infections [7, 8]. The rank order of Candida 
in bloodstream infections varies by country and is influ-
enced by the type of patients studied. Candida is number 
three or four in mostly ICU-based US studies and num-
ber six to ten in population-based European studies [9]. 
The incidence of candidemia is age-related with higher 
frequencies at both ends of the spectrum. Globally, inva-
sive candidiasis ranges from 1 to 10 per 1000 ICU admis-
sions. While it is responsible for no more than 5% of the 
total number of sepsis or septic shock, candidemia is 
associated with sepsis or septic shock in 10–40% of cases 
[10].
Conventional culture-based microbiological tests are 
suboptimal for the diagnosis of candidemia and deep-
seated candidiasis. Blood cultures are insensitive and 
take several days to obtain Candida species and antifun-
gal susceptibilities [11]. Although fluorescence in  situ 
hybridization with peptide nucleic acid probes (PNA-
FISH) allows the detection of yeasts within 30–90  min 
of blood culture positivity, the commercially available 
test (PNA-FISH Yeast Traffic Light assay) does not dis-
tinguish between C.  albicans and C.  parapsilosis or 
C. glabrata and C. krusei.
Various studies have shown that delays in initiat-
ing adequate antifungal therapy are associated with 
increased mortality [12, 13], therefore driving the field to 
explore advanced strategies such as prophylaxis, marker-
based pre-emptive therapy, and risk-based empirical 
therapy. Numerous risk factors for invasive Candida 
infections have been identified, including higher Acute 
Physiology and Chronic Health Evaluation  II scores, 
diabetes mellitus, renal insufficiency, surgery (especially 
abdominal surgery), pancreatitis, the use of broad-spec-
trum antibiotics, parenteral nutrition, hemodialysis, 
mechanical ventilation, the presence of central vascular 
catheters, and therapy with immunosuppressive agents 
[9]. The development of invasive Candida infections is 
often preceded by extensive colonization of the skin or 
of the mucus membranes of the gastrointestinal and uro-
genital tracts, and the degree of colonization, assessed 
using the colonization index, has been shown to be an 
independent risk factor for development of candidiasis 
[9]. Fluconazole and caspofungin decrease the incidence 
of invasive candidiasis when given prophylactically in 
selected patients [14, 15]. Biomarker-guided pre-emptive 
therapy with echinocandins triggered by elevated serum 
β-1 → 3-d-glucan (BDG) has also been shown to reduce 
the incidence of proven disease and to target antifungals 
for patients that would be most likely to benefit from 
them [15]. While fluconazole has not been shown to be 
effective for empirical therapy [16], a recent study has 
shown that empirical therapy with micafungin in high-
risk hosts also decreased the incidence of proven disease 
[17]. None of these studies have shown a survival benefit 
as none of them have been powered to do so; however, 
the standard of care at this time is utilizing a clinical pre-
diction rule such as the Candida score [18] or the MSG-
01 rule [15] to identify high-risk hosts and then monitor 
serum biomarkers such as BDG or PCR for biomarker-
based pre-emptive therapy or the clinical prediction rules 
themselves as triggers for empirical therapy. A recent 
study has also shown that the negative predictive value of 
BDG can be used to stop empirical therapy as part of an 
antifungal stewardship intervention [19].
Polyenes, azoles, and echinocandins are the antifungal 
drug classes available for the treatment of invasive can-
didiasis (Table  1). All new antifungal drugs have been 
compared to a standard regimen in one or more ran-
domized trials. In the 1990s, fluconazole became the 
standard treatment regimen for invasive candidiasis, as 
it was shown to be as effective as conventional ampho-
tericin B deoxycholate (dAmB), but associated with sig-
nificantly lower toxicity [20]. Since those trials, dAmB 
is no longer considered a treatment option for invasive 
candidiasis [21]. Also voriconazole and caspofungin were 
shown to be as effective as dAmB but less toxic [22, 23]. 
Subsequently, in two randomized trials, micafungin was 
shown to be as effective as caspofungin and as liposomal 
amphotericin B (LAmB) [24, 25].
Despite the limited but significant advent of Candida 
strains with reduced susceptibility to fluconazole (espe-
cially C. glabrata), the drug has remained the mainstay of 
anti-Candida treatment for more than two decades.
Invasive aspergillosis
The incidence of invasive pulmonary aspergillosis (IPA) 
in the ICU is unclear, ranging from 0.3% to 19% because 
of the difficulties of diagnosis (diagnostic tests vary in 
their sensitivity and specificity) and related to biopsy 
or autopsy difficulties in the ICU setting (coagulation 
abnormalities, difficult oxygenation, next of kin consent 
for autopsy, etc.) [26]. The “classical” risk factors for IPA 
are classified in high, intermediate, and low risk cat-
egories (Table  2). New risk factors, however, have been Ta
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identified during the last decade including COPD, liver 
failure, cirrhosis, and post-H1N1 influenza [27, 28]. The 
diversity of patients and risk factors complicates diagnos-
tic and therapeutic procedures while the available data in 
critically ill patients are extremely limited.
What have been the major recent advances in the field?
Invasive candidiasis
Geographical and environmental factors, the patient’s 
age, and exposure to antimicrobial agents impact on the 
distribution of Candida species isolated from patients 
with invasive candidiasis (IC). Historically, C.  albicans 
was responsible for about two-thirds of IC, but non-
albicans Candida species (i.e., C. glabrata, C. krusei, C. 
tropicalis, and C.  parapsilosis) now account for about 
half of all cases of IC in hospital [10]. The proportion of 
IC due to C.  glabrata has increased in Western coun-
tries (i.e., Europe and North America) and tends to be 
higher in older patients [9, 10]. C.  parapsilosis is more 
predominant in Southern Europe, Southeast Asia, and 
Latin America [10]. The occurrence of infections caused 
by C. krusei or by C. glabrata had been linked to previous 
exposure to antifungal agents, especially azoles. C. dub-
liniensis, C. guilliermondii, C. kefyr, and C. lusitaniae 
species are a less frequent cause of IC [9] C. auris is an 
emerging, multidrug-resistant yeast causing invasive 
healthcare-associated infections [29].
Matrix-assisted laser desorption ionization–time of 
flight mass spectrometry (MALDI-TOF MS) has over-
come several of the shortcomings of conventional micro-
biology for the detection and identification of yeasts 
[30–32]. Turnaround times are 10–15  min after the 
growth of a fungal colony or a positive blood culture, 
and diagnostic accuracy is over 95%. Additional work 
is required to make MALDI-TOF MS suitable for the 
detection of antifungal resistance [33].
Over the last few decades, non-culture-based diagnos-
tic methods have been developed to detect fungal metab-
olites, cell wall antigens (mannan and BDG), nucleic 
acids, and antibodies directed against fungal products in 
blood and other body fluids. A meta-analysis showed that 
the detection of mannan antigen and anti-mannan anti-
bodies had low sensitivities (around 60%) but high specif-
icities (90–95%) for the diagnosis of IC [34]. Combining 
antigen and antibody assays increased the sensitivity to 
83% but not the specificity. Sensitivities are higher for 
infections caused by C. albicans than by other Candida 
species. Commercially available BDG assays had sensitiv-
ities of 73–75% and specificities of 97% for the diagnosis 
of probable or proven Candida infections [35].
Up to two-thirds of adult ICU patients receive empiri-
cal systemic antifungal treatment (ESAT) [21, 36]. 
Although early ESAT has been recommended in patients 
with risk factors for invasive candidiasis (IC), sepsis of 
unknown cause, and positive Candida serum biomark-
ers BDG and Candida albicans germ tube antibody 
(CAGTA) [37], its usefulness and influence on outcome 
need to be confirmed.
In the challenging scenario of early diagnosis of IC, 
recent studies have demonstrated the diagnostic value of 
BDG and CAGTA [19, 38–42]. Although the use of BDG 
measurement in daily practice for establishing the indica-
tion or the withdrawal of ESAT should be defined, recent 
observational studies [41, 42] showed that negativity of 
the BDG assay may be used as a strategy to discontinue 
ESAT because of the high sensitivity and negative predic-
tive value of the test. Until new proteomic (MALDI-TOF) 
or genomic (PCR) techniques could be extrapolated to 
IC for improving its diagnosis, a therapeutic algorithm 
based on stratification of the clinical condition, Candida 
score, and results of Candida serum biomarkers may be 
useful to improve the management of ICU patients at 
high risk of invasive fungal infection (Fig. 1).
In a pivotal randomized trial, anidulafungin was com-
pared to fluconazole for the treatment of candidemia 
and invasive candidiasis in non-neutropenic patients 
[5]. In that study, the overall response was significantly 
better with anidulafungin (76%) than with fluconazole 
(60%; P  <  0.01). The inferior outcomes with flucona-
zole were retained in post hoc multivariate analyses, 
Table 2 Risk factors for IPA in ICU patients
COPD chronic obstructive pulmonary disease, HIV human immunodeficiency 
virus, HSCT hematopoietic stem cell transplantation, ICU intensive care unit, IPA 
invasive pulmonary aspergillosis
1. High risk
 Neutropenia (500/mm3)
 Hematological malignancy
 Allogeneic HSCT
2. Intermediate risk
 Prolonged treatment with corticosteroids before admission to the ICU
 Autologous HSCT
 COPD
 Liver cirrhosis
 Solid organ cancer
 HIV infection
 Lung transplantation
 Systemic immunosuppressive therapy
3. Low risk
 Severe burns
 Solid organ transplant
 Steroid treatment for >7 days
 Prolonged stay in the ICU (>21 days)
 Malnutrition
 Post cardiac surgery
 Near drowning
and the difference was consistent over a broad range of 
APACHE II scores [43]. Interestingly, while the infecting 
C. albicans strains were uniformly susceptible to flucon-
azole, the inferiority of fluconazole was most prominent 
in patients infected by C. albicans (success rate, flucona-
zole 62% vs. anidulafungin 81%; P < 0.02) [5]. In addition, 
while the trial was not powered for mortality differences, 
the mortality in the fluconazole group tended to be higher 
than in the anidulafungin group (31% vs. 23%; P = 0.13).
On the other hand, the influence of severe pathophysio-
logical changes that are present in the critically ill patient 
may also cause pharmacokinetic (PK) alterations of the 
different antifungals [44, 45]. Recent studies showed that 
echinocandins exposure in ICU patients was low com-
pared with healthy volunteers and other (non-)critically 
ill patients, most likely as a result of a larger volume of 
distribution, suggesting that a weight-based dose regi-
men should probably be more suitable for patients with 
substantially altered drug distribution [45–47].
Invasive aspergillosis
Early diagnosis of IPA is a challenge based on the inte-
gration of microbiological, radiological, and clinical data. 
The laboratory diagnosis is based on galactomannan 
Systemic antifungal therapy in ICU patients: an approach based in clinical 
stratification, Candida scores and Candida biomarkers
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surgery/Medical
HIGH                                      LOW
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Fig. 1 Systemic antifungal therapy in ICU patients: an approach based on clinical stratification, Candida scores and Candida biomarkers. CI Coloni‑
zation index (range, 0–1) indicates the number of positive sites colonized with Candida divided by the number of sites sampled, CS Candida score 
(range, 0–5) items are surgical admission (1 point), severe sepsis (2 points), multiple sites positive with Candida species (1 point), and parenteral 
nutrition (1 point), * Candida biomarkers: (1→3)‑ß‑D‑glucan (ßDG) and Candida albicans germ tube antibody (CAGTA), ** Positive: ßDG ≥cutoff in 
two consecutive samples or ßDG and CAGTA ≥cutoff in one determination
(GM) detection in bronchoalveolar lavage (BAL) speci-
mens (GM cutoff 0.5–1.0) and not in serum (BAL GM 
sensitivity 66.7%, serum GM sensitivity 53.3%). There is 
a limited role for BDG testing alone, although the com-
bination with GM or PCR improves specific detection 
[48]. The Aspergillus lateral flow device (LFD) assay in 
serum and BAL samples—a rapid test for the detection 
of Aspergillus—is not yet commercially available, whilst 
the SeptiFast assay method in blood samples is associ-
ated with a sensitivity of 66%, specificity 98%, PPV 93%, 
and NPV 88% [49]. CT scanning of the lungs is associ-
ated with greater than 90% specificity and poor sensi-
tivity (30–40%). In critically ill COPD patients multiple 
nodules distributed along with bronchovascular bundles 
are common, whilst a deteriorating chest X-ray com-
bined with laboratory tests could support the diagnosis 
of probable IPA. The clinical signs and symptoms are 
non-specific. Because of all these diagnostic uncertainties 
and difficulties, an algorithm by AspICU investigators 
has been suggested in order to facilitate the diagnosis of 
probable IPA in the ICU setting (Table 3) [50].
What are the common beliefs that have been contradicted 
by recent trials and what are remaining areas 
of uncertainty?
Invasive candidiasis
IC is associated with an overall crude mortality of 
40–60%, which is strongly affected by the underlying 
conditions and by the presence of sepsis or septic shock 
[10]. Assessing the attributable mortality of IC is diffi-
cult, with studies estimating ranges from 5% to 70% [51]. 
However, it is most likely in the range of 10–15% [9]. Spe-
cies-specific survival analyses have yielded ambiguous 
results in large patient cohorts.
Although use of preemptive therapy is gaining interest, 
more studies are needed to better define which patients 
may benefit from this approach and whether more wide-
spread use of antifungal agents may negatively influence 
fungal ecology. A recent double-blind placebo-controlled 
trial has also contradicted the widespread belief that 
critically ill patients with ICU-acquired sepsis, Candida 
colonization, and multiple organ failure should receive 
antifungal therapy. In this clinical trial, empirical treat-
ment with micafungin, compared with placebo, did not 
increase fungal infection-free survival at day 28 (primary 
endpoint). However, this trial was not powered to detect 
changes in mortality [17].
Despite some studies showing the superiority of echi-
nocandins over fluconazole, a propensity score-derived 
analysis of a population-based, multicenter prospective 
cohort has demonstrated that, in patients with candi-
demia, therapy with fluconazole did not show a signifi-
cant association with mortality either in the empirical or 
targeted therapy [52]. These results were similar among 
patients with severe sepsis and septic shock. In patients 
with septic shock attributable to Candida spp., after 
Table 3 A clinical algorithm to diagnose IPA in critically ill patients
1. Aspergillus (+) LRT specimen culture (entry criterion)
2. Compatible signs and symptoms (one of the following)
 Fever refractory to at least 3 days of appropriate antibiotic therapy
 Recrudescent fever after a period of defervescence of at least 48 h while still on antibiotics and without other apparent cause
 Pleuritic chest pain
 Pleuritic rub
 Dyspnea
 Hemoptysis
 Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support
3. Abnormal medical imaging by portable chest X‑ray or CT scan of the lungs
4. Either
4a. Host risk factors (one of the following conditions)
 Neutropenia (absolute neutrophil count less than 500/mm3) preceding or at the time of ICU admission
 Underlying hematological or oncological malignancy treated with cytotoxic agents
 Glucocorticoid treatment (prednisone or equivalent, >20 mg/day)
 Congenital or acquired immunodeficiency
OR
4b. Semiquantitative Aspergillus‑positive
 Culture of BAL fluid (+ or ++) without bacterial growth together with a positive cytological smear showing branching hyphae
a) Probable invasive pulmonary aspergillosis when 1 + 2 + 3 + either 4a or 4b
b) When ≥1 criterion is not met, the case is classified as Aspergillus colonization
adjustment for severity of illness and source control, 
therapy with echinocandins was not associated with a 
higher survival rate [53]. Two other recent observational 
studies have confirmed that antifungal choice (flucona-
zole vs. echinocandin/liposomal-amphotericin  B) does 
not influence mortality in C. glabrata bloodstream infec-
tion [53, 54]. More data are needed in this area.
Pathophysiological changes associated with critical ill-
ness can change drug concentrations so that they are sig-
nificantly different from those observed in non-critically 
ill patients. In these circumstances, if standard dosing 
is used, then suboptimal concentrations (either too low 
or unnecessarily high) may result, putting the patient at 
risk of clinical failure or drug toxicity. Antifungal agents 
tend not to be as markedly affected by altered PK in criti-
cal illness. The drugs are mostly lipophilic, hepatically 
metabolized, and with high protein binding. Drugs such 
as fluconazole are an exception to these characteristics. 
Use of renal replacement therapy (RRT) can influence 
the clearance of some antifungal drugs, particularly those 
that are predominantly eliminated by renal mechanisms, 
are not highly protein bound, and have low molecular 
weights, notably the azoles and 5-flucytosine. Moreo-
ver, different RRT characteristics, including the specific 
mode, membrane characteristics, flow rates, and dura-
tion of treatment, may influence the effects of RRT on 
drug PK and should be taken into consideration when 
evaluating dosing [6, 9].
Source control, i.e., catheter removal during candi-
demia or abscess drainage in invasive candidiasis, has 
proven an independent predictor of reduced mortality 
in multiple studies [12, 55]. The optimal total duration 
of therapy for candidemia and invasive candidiasis has 
not been studied. However, step-down from echinocan-
dins to intravenous or oral azoles appears to be feasible, 
once the patient has been stabilized, and provided that 
the isolate is azole-susceptible. While most trials allowed 
step-down to azoles after at least 10 days of echinocan-
din therapy, a recent non-comparative trial applied a 
step-down to an oral azole as early as 5  days after start 
of iv treatment [56]. In a prospective cohort study of ICU 
patients, neither discontinuation of empirical antifungal 
therapy nor de-escalation to fluconazole after 5  days in 
the case of documented invasive candidiasis was associ-
ated with a survival difference [57]. Although these stud-
ies were not randomized to compare early step-down 
therapy to prolonged echinocandins, the efficacy and 
survival results in patients with early step-down were 
similar.
Invasive aspergillosis
For the treatment of IPA voriconazole and isavuconazole 
are recommended, whilst LAmB or AmB lipid complex 
is recommended for species with intrinsic high azole 
minimum inhibitory concentrations (MICs). Voricona-
zole is recommended for IPA due to A.  fumigatus if the 
isolate is voriconazole-susceptible (susceptible if MIC 
≤1 mg/L) whilst in the case of resistance (MIC >2 mg/L) 
LAmB therapy is preferred. Where the voriconazole MIC 
equals 2  mg/L (intermediate) the response to voricona-
zole monotherapy is unknown [58]. A growing problem 
in IPA treatment is the intrinsic resistance to polyenes 
and azoles or the acquired resistance to azoles during 
azole therapy mainly in patients with chronic pulmonary 
aspergillosis (CPA) [59]. TDM is used to avoid treatment 
failure, resistance, or toxicity. The optimal plasma trough 
levels (with HPLC/MS) are 1–4  mg/L for itraconazole, 
2–6 mg/L for voriconazole, and greater than 1 mg/L for 
posaconazole suspension [60–62]. The newer tablet or 
intravenous formulation of posacoanzole is more likely to 
achieve target plasma levels but there is limited evidence 
for routine TDM. Data supporting routine TDM for isa-
vuconazole are also limited, although from phase II/III 
clinical studies trough levels of 2–3 mg/L are suggested.
The use of combination antifungal therapy for IA 
is debated, although theoretically this can achieve (a) 
potential synergistic effects, (b) broader antifungal spec-
trum, and (c) potentially a reduction of acquired resist-
ance [63]. In  vitro and animal studies demonstrated 
synergistic or additive effects of a mold-active triazole 
(itraconazole, voriconazole, or posaconazole) or ampho-
tericin  B with an echinocandin but few human studies 
support this practice. The combination of voriconazole 
with anidulafungin failed to demonstrate an overall sig-
nificant difference over voriconazole alone in primary 
outcome in IPA cases, although in a post hoc subgroup 
analysis among galactomannan-positive patients a sig-
nificant advantage favoring combination treatment was 
recorded [64]. The use of combination therapy is consid-
ered as therapeutic solution (a) in cases of resistance (e.g., 
Cyp51a mutations), (b) in central nervous system asper-
gillosis due to azole-resistant Aspergillus (favoring flu-
cytosine), (c) as broad initial coverage pending pathogen 
identification, (d) for salvage therapy in refractory disease 
[65]. In regions with environmental resistance rates of 
at least 10%, a voriconazole–echinocandin combination 
could be used as initial therapy [66]. The duration of IPA 
treatment ranges between 3 and 50  weeks. Physicians 
should consider iv to oral switch in stable patients and, 
before treatment discontinuation, is essential the closed 
monitoring with imaging and microbiological evaluation.
Chronic pulmonary aspergillosis (CPA) is a rare dis-
ease in non-immunocompromised patients with prior 
or current lung disease including tuberculosis, chronic 
cavitary pulmonary aspergillosis (CCPA), chronic fibros-
ing pulmonary aspergillosis (CFPA), Aspergillus nodules 
and single aspergilloma, which in moderately immuno-
compromised patients present as subacute invasive pul-
monary aspergillosis (formerly called chronic necrotising 
pulmonary aspergillosis) leading to a more rapidly pro-
gressive infection (<3 months) which should be managed 
as invasive aspergillosis.
The diagnosis of CPA requires the combination of 
thoracic imaging findings, direct evidence of Aspergil-
lus infection (microscopy or culture from biopsy) or 
immunological response to Aspergillus spp., and exclu-
sion of alternative diagnoses, all present for at least 
3  months. Long-term oral antifungal therapy is recom-
mended, whilst surgical excision of simple aspergilloma 
is suggested if technically possible. Hemoptysis may be 
controlled with tranexamic acid and bronchial artery 
embolization [67].
What are remaining areas of uncertainty?
Invasive candidiasis
Given the ubiquitous presence of glucan in the environ-
ment, false-positive BDG results have been noted in a 
number of conditions frequently encountered in criti-
cally ill patients such as severe mucositis, bacterial sep-
sis, hemodialysis, treatment with antibiotics, albumin, 
or immunoglobulins, and transfusion of human blood 
products. BDG was superior to the Candida score or the 
colonization index for the diagnosis of intra-abdominal 
candidiasis or candidemia in high-risk surgical and ICU 
patients [68, 69]. However, undetectable serum BDG 
does not rule out an early IFI when the clinical suspicion 
is high [70].
The detection of fungal DNA by PCR is a technical 
challenge because of a low DNA yield after cell lysis and 
the risk of false positivity due to contamination by fun-
gal saprophytes. A broad range of in-house PCR methods 
have been developed but there still is no commercially 
available PCR assay. In a systematic review and meta-
analysis, PCR tended to be positive at an earlier time 
point than conventional microbiology with pooled sensi-
tivity and specificity of PCR for candidemia of 95% and 
92%, respectively [71]. In a recent study, plasma or serum 
PCR was more sensitive than BDG in patients with IC 
or deep-seated candidiasis (80% versus 56% and 88% 
versus 62%, respectively) but not in those with candi-
demia [72]. Sensitivities reached 98% when blood culture 
was combined with PCR. A whole blood assay combin-
ing PCR technology and nanoparticle-based hybridi-
zation (T2 magnetic resonance) was recently shown 
to rapidly (<5  h), accurately, and reproducibly detect 
1–3 CFU of C. albicans, C. tropicalis, C. glabrata, C. kru-
sei, and C.  parapsilosis per milliliter of spiked blood 
or in patients with a low incidence of IC [73]. Lately, a 
PCR/electrospray ionization–mass spectrometry (PCR/
ESI) technology was developed to detect more than 800 
bloodstream infection-relevant bacterial and Candida 
species within 6  h of sample acquisition. Findings from 
the RADICAL study showed 81% sensitivity, 69% speci-
ficity, and 97% negative predictive value with PCR/ESI 
when compared with conventional cultures [74]. In a 
set of prospectively collected blood samples in sepsis 
patients, PCR/ESI and standard microbiology were con-
cordant in 86% of culture-positive samples [75]. Of note, 
the PCR/ESI assay is not capable of determining antimi-
crobial resistance phenotypes, and the inclusive detection 
of resistance-associated genotypes is, to date, limited to 
only few broad-spectrum antibiotic resistance markers.
Many questions about the proper management of fun-
gal infections still exist without definitive answers. The 
absence of definite diagnostic criteria in patients with 
suspicion of non-candidemic invasive candidiasis makes 
it clearly difficult to determine the efficacy of differ-
ent therapeutic approaches. In fact, the negative results 
of ESAT in the recent clinical trial can be explained by 
the fact that many of these patients did not truly have an 
invasive candidiasis despite the fact that all had sepsis, 
multiple organ failure, and multifocal Candida coloniza-
tion [17].
Although several diagnostic algorithms based on the 
combination of clinical scores and microbiological tests 
have been proposed, this approach did not discriminate 
infected from non-infected patients. New diagnostic 
tools with higher sensitivity and specificity are clearly 
needed. For the rapid diagnosis of Candida bloodstream 
infections, technologies such as MALDI-TOF allow the 
direct identification of bacteria from positive blood cul-
tures whereas yeasts are poorly identified using this tech-
nique [76, 77]. New technologies (i.e., fluorescence in situ 
hybridization) [78] capable of identifying Candida spp. 
in blood cultures within a few hours are highly attractive, 
but clinical studies are needed to establish the clinical 
benefits of these diagnostic tools and how to introduce 
them into the diagnostic work-up. T2 diagnostic technol-
ogy is an exciting development in the field, but more real-
world experience is needed [73, 79].
Recent studies have also cast doubt about the optimal 
dosing of antifungals in critically ill patients, especially in 
more severe condition [80]. There are also emerging data 
linking suboptimal dosing to the emergence of antifun-
gal resistance and a poor outcome. Dosing of antifun-
gal agents in patients with extracorporeal devices needs 
more studies to define the therapeutic schemes that avoid 
subtherapeutic levels. In this sense, the impact on out-
come of TDM warrants further investigations.
Despite the publication of the randomized trial sug-
gesting the superiority of anidulafungin compared to 
fluconazole [5], physicians have continued to prescribe 
fluconazole with candidemia or invasive candidiasis, sup-
ported by some of the guidelines. Many physicians have 
long favored fluconazole over the new echinocandins, 
driven by the vast clinical experience with fluconazole, its 
favorable pharmacokinetics and tissue penetration, and 
its low price compared to echinocandins.
Recently, a second, large randomized trial comparing 
azoles to echinocandins as initial therapy for candidemia 
or invasive candidiasis demonstrated a similar differ-
ence. In that study, the success rate in the isavuconazole 
group was 60.3% vs. 71.1% in the caspofungin group [81]. 
A pooled analysis was performed of patient-level data 
from seven randomized antifungal treatment trials, using 
30-day mortality as the primary endpoint [55]. In this 
analysis, randomization to an echinocandin was associ-
ated with significantly greater clinical success and better 
survival than treatment with amphotericin  B or azoles. 
The advantage of echinocandin therapy over azoles was 
demonstrated in patients with low and moderately high 
APACHE  II scores, suggesting that the survival benefit 
from echinocandin treatment is not limited to severely 
ill patients [55]. Multiple cohort studies have identified 
treatment with an echinocandin to be independently 
associated with better survival in multivariate analyses, 
e.g., in severely ill patients with candidemia and septic 
shock [82], and in patients infected by C. glabrata [83].
Despite the lack of randomized trials, antifungal ther-
apy for patients with severe community-acquired or 
healthcare-associated intra-abdominal infection is rec-
ommended if Candida is grown from cultures [9, 84].
As patients with candidemia are easier to recognize and 
to enroll in clinical trials than patients with deep-seated 
candidiasis, trial results and guidelines have mainly 
focused on patients with candidemia [9]. Specific studies 
will need to identify the optimal diagnosis and treatment 
of deep-seated abdominal candidiasis.
In a large clinical study, ICU patients with polymor-
phisms in their TLR/interferon-α host defense pathway 
were more likely to develop candidemia than underlying 
disease-matched ICU controls [85]. A genome-wide anal-
ysis has identified several additional immune polymor-
phisms that render patients up to 19 times more likely 
to acquire candidemia than other ICU patients [86]. 
These findings may lead to screening strategies to iden-
tify patients at risk and requiring antifungal prophylaxis, 
early empiric therapy, or adjunctive immunotherapy 
when undergoing surgery or ICU admission [87].
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The survival of patients with IPA has increased in recent 
years owing to advances in diagnosis and the release of 
newer antifungal drugs, but the overall outcome still 
remains suboptimal (attributable mortality is considered 
42–64%) especially in certain populations (e.g., allogeneic 
HSCT) or in cases of extrapulmonary involvement [63]. 
According to Taccone et al., the mortality predictors for 
critically ill with IPA include age, SOFA score, mechani-
cal ventilation, and renal replacement therapy at diagno-
sis [26, 88].
What do the international group of experts recommend 
as the top 10 studies/trials to be done in the next 10 years 
and what are expected outcomes/results of these trials?
Invasive candidiasis
Recent observations emphasize the necessity to build 
a worldwide sentinel network to collect epidemiologi-
cal data in real time in order to monitor the emergence 
of new fungal species causing IC and changes in suscep-
tibility of the most common isolates. Obtaining robust 
data on the attributable mortality of IC is critical for the 
design of clinical studies with mortality endpoints.
Despite enormous progress made in mycological diag-
nostics, molecular methods relying on culture amplifica-
tion remain inadequate to fill the temporal gaps between 
the release of a laboratory result and the identity of 
causative fungal pathogens and susceptibility patterns. 
Upcoming molecular methods applied directly to clinical 
specimens may greatly accelerate diagnosis and signifi-
cantly impact on early therapy of IFIs. Trade-offs in terms 
of increased sensitivity include the risk of false-positive 
results due to environmental fungal DNA contamination. 
Yet, fully automated molecular tests may help reduce 
the risk of contamination, workload, and error rates and 
thus offer the promise of short turnaround time which 
is essential for early diagnosis and prompt initiation of 
appropriate therapy for IFIs.
As the discussion has highlighted, the recent years have 
seen the development of various new biomarkers for the 
diagnosis and management of candidemia and invasive 
candidiasis, along with a better appreciation and valida-
tion of various clinical stratification tools. Hence, we sug-
gest three potential studies that should help to elucidate 
our understanding of these severe infections. First, it 
remains unclear how the use of biomarkers can be differ-
entially integrated into pre-emptive therapy strategies. A 
randomized controlled trial linking change in biomarkers 
and a clinical risk score as part of a pre-emptive treatment 
strategy as compared to standard therapy would provide 
substantial insight. Second, with expanding utilization 
of procalcitonin (PCT) to guide anti-infective treatment 
initiation and duration, there remains a paucity of knowl-
edge about if and how this test can be applied in cases 
of either suspected or confirmed candidemia or invasive 
candidiasis. Simple observational studies to appreci-
ate the natural history of changes in PCT in candidemia 
are necessary as are studies to define the sensitivity and 
specificity of this test for non-bacterial processes. Third, 
with the advent of new biomarkers and expanding data 
to explain the value and limitations of older ones, we sug-
gest a randomized controlled study employing multiple 
biomarkers and changes in them to guide initiation and 
duration of therapy. We envision moving to a scenario 
much akin to venous thromboembolism, where a risk 
score stratifies pretest probability formally and then bio-
markers with high sensitivity are measured and followed 
by an assessment of biomarkers with enhanced specific-
ity—so as to decrease the number of patients unnecessar-
ily exposed to antifungal therapy.
For the management of patients with invasive candidi-
asis, future studies may specifically address the optimal 
diagnostic and therapeutic strategies for patients with 
deep-seated abdominal candidiasis or Candida perito-
nitis. These patients are currently often underdiagnosed; 
while it is assumed that echinocandins constitute the opti-
mal treatment regimen, specific studies on treatment of 
abdominal candidiasis are lacking. Second, better knowl-
edge of PK of antifungal molecules and tissue penetration 
is a key issue for intensivists. The optimal dosing schedule 
for echinocandins in ICU patients in not known. Given 
the inter-individual variability observed in ICU patients, 
the role of TDM should be studied further. Third, identifi-
cation of immunogenetics-based risk profiles may identify 
patients at highest risk for invasive candidiasis, leading to 
personalized antifungal prophylaxis or treatment. Finally, 
new antifungal drugs are currently under development. 
At least three compounds are under development: a long-
acting echinocandin (CD101, Cidara) and two entirely 
new antifungal classes (SCY078, Scynexis, and APX001, 
Amplyx) will enter phase 2/3 candidemia/invasive can-
didiasis trials shortly. These new drugs and new person-
alized antifungal strategies may contribute to optimal 
management and lower mortality rates among patients 
with candidemia or invasive candidiasis.
Invasive aspergillosis
During the last decade significant progress regarding 
epidemiology, diagnosis, and treatment of IPA has been 
recorded. However, further investigation is needed for 
topics including (a) the incidence of IPA in the ICU, (b) 
the relationship between IPA and influenza outbreaks, 
(c) the clinical impact of the Aspergillus LFD and Septi-
Fast assay in the rapid diagnosis, (d) the significance of 
combination treatment (patients’ outcome, impact of PK/
PD profile of combined antifungal molecules), and (e) the 
extrapulmonary manifestation of aspergillosis (mediasti-
nitis after cardiac surgery, pericarditis/endocarditis).
Conclusions
As a result of epidemiologic changes, the continuing evo-
lution of pathogens and new patient groups at risk, infec-
tious diseases scientists and physicians can never be fully 
satisfied with the tools at hand. However, during recent 
years, the scientific community made significant progress 
in epidemiology, diagnosis, and treatment of IFI. This is 
Table 4 Top 10 studies/trials to be done in the next 10 years
Studies/trials Expected outcome/results
1. Worldwide sentinel network to collect epidemiological data in real time Monitor emergence of new fungal species and changes in susceptibility of 
the most common isolates
2. A randomized controlled trial linking change in biomarkers and a clini‑
cal risk score as part of a pre‑emptive treatment strategy as compared to 
standard therapy
Provide substantial insight to better define pre‑emptive strategy
3. Utilization of PCT to guide treatment initiation and duration Provide knowledge about if and how this test can be applied in cases of 
either suspected or confirmed candidemia or invasive candidiasis
4. Specific study on the treatment of abdominal candidiasis (drug, dose, 
duration)
Better knowledge about optimal management
5. Study on PK/PD and TDM of antifungal molecules in critically ill patients Better knowledge about tissue penetration of echinocandins, optimal dos‑
ing schedule for echinocandins, when and how to do TDM
6. Identification of immunogenetics‑based risk profiles for identifying 
patients at highest risk for invasive candidiasis
Personalized antifungal prophylaxis or treatment
7. Phase 3 Studies on new antifungals (CD101, SCY078, and APX001) These new options may contribute to optimal management and lower 
mortality rates among patients with candidemia or invasive candidiasis
8. The clinical impact of the Aspergillus LFD and SeptiFast assay in the rapid 
diagnosis of invasive aspergillosis
Easier and more rapid diagnosis of invasive aspergillosis
9. The significance of combination treatment patients’ outcome and 
impact of PK/PD profile of combined antifungal molecules
Better knowledge about combination therapy in patients with invasive 
aspergillosis
10. Study on incidence of extrapulmonary manifestation of aspergillosis Better knowledge about the epidemiology and the management of medi‑
astinitis after cardiac surgery and pericarditis/endocarditis
an excellent foundation on which to build the next steps 
of improvement. Further investigation aims to reduce 
the still high morbidity and mortality of IFI, and to raise 
awareness of IFI among clinicians.
Combining clinical and microbiological expertise, we 
recommend the following array of research topics for the 
agenda of the immediate decade (Table 4).
A worldwide sentinel network needs to collect data on 
emerging pathogens, changing susceptibility patterns, 
and IFI-attributable mortality in real time. Studies on 
accelerated diagnosis would allow earlier targeted treat-
ment and should emphasize molecular characterization 
of cultured pathogens and ideally the direct application 
of molecular methods to clinical specimens. The rand-
omized comparison of experimental treatment strategy 
integrating clinical stratification and old and new bio-
markers with current treatment standard would provide 
valuable strategic insights. At the same time studies on 
biomarkers should guide clinical decision-making on the 
fundamental issues of when to start and when to stop 
antifungal treatment. A less well-studied clinical issue is 
the various forms of deep-organ IFI, ranging from bone 
and joint to intra-abdominal infection. In critically ill 
patients, studies on antifungal PK, tissue penetration, 
and optimal dosing schedules would elucidate the role 
of TDM. Finally, studies on immunogenetic risk pro-
files could eventually lead to personalized antifungal 
strategies.
Researching the above topics will advance our knowl-
edge of IFI and will allow decisive development against 
fungal morbidity and mortality in critically ill patients. 
Current industrial drug development plans may address 
some of the agenda items, but the vast majority goes 
beyond the interest and capability of the pharmaceutical 
industry and requires action of public funding bodies.
Abbreviations
BDG: β‑1 → 3‑d‑glucan; CAGTA: Candida albicans germ tube antibody; CCPA: 
Chronic cavitary pulmonary aspergillosis; CFPA: Chronic fibrosing pulmonary 
aspergillosis; CPA: Chronic pulmonary aspergillosis; ESAT: Empirical systemic 
antifungal treatment; GM: Galactomannan; HSCT: Halogenic stem cell 
transplant; IC: Invasive candidiasis; IFI: Invasive fungal infections; IPA: Invasive 
pulmonary aspergillosis; LAmb: Liposomal amphotericin B; LFD: Lateral flow 
device; MALDI‑TOF MS: Matrix‑assisted laser desorption ionization–time 
of flight mass spectrometry; PCT: Procalcitonin; TDM: Therapeutic drug 
monitoring.
Author details
1 Infectious Diseases Clinic, Santa Maria Misericordia Hospital, University 
of Udine, Udine, Italy. 2 Unidad Clínica de Cuidados Intensivos, Hospital 
Universitario Virgen Macarena and Institute of Biomedicine of Seville, IBiS/
CSIC/University of Seville, seville, Spain. 3 Infectious Diseases Service, 
Department of Medicine, Centre Hospitalier Universitaire Vaudois, University 
of Lausanne, Lausanne, Switzerland. 4 Department of Medicine and Rad‑
boud Center for Infectious Diseases, Radboud University Medical Center, 
Nijmegen, Netherlands. 5 Department of Critical Care, University Hospital 
ATTIKON, National and Kapodistrian University of Athens, Athens, Greece. 
6 Medical Intensive Care Unit, Hôpital Saint‑Louis, ECSTRA Team, Biostatistics 
and Clinical Epidemiology, Paris Diderot Sorbonne University, Paris, France. 
7 Department of Medical Microbiology, Postgraduate Institute of Medical 
Education and Research, Chandigarh, India. 8 Division of Pulmonary and Criti‑
cal Care Medicine, The Leonard M. Miller School of Medicine at the University 
of Miami, Miami, FL, USA. 9 Intensive Care Unit, Hospital Universitario de 
Valme, Universidad de Sevilla, Seville, Spain. 10 Division of Infectious Diseases, 
McGovern Medical School, UTHealth, Houston, USA. 11 Institute of Microbiol‑
ogy, Università Cattolica del Sacro Cuore, Rome, Italy. 12 1UMR1137‑IAMETeam 
5, Decision Sciences in Infectious Disease Prevention, Control and Care, Paris 
Diderot University‑Inserm, Sorbonne Paris Cité and 2AP‑HP, Medical and Infec‑
tious Diseases ICU, Bichat Hospital, Paris, France. 13 Division of Infection, 
Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, 
Manchester Academic Health Science Centre, The University of Manchester, 
Manchester, UK. 14 Pulmonary and Critical Care Medicine, Medstar Wash‑
ington Hospital Center, Washington, USA. 15 Cologne Excellence Cluster 
on Cellular Stress Responses in Aging‑Associated Diseases (CECAD), Clinical 
Trials Centre Cologne (ZKS Köln), Department I of Internal Medicine, German 
Centre for Infection Research (DZIF), University of Cologne, Cologne, Germany. 
16 Clinica Malattie Infettive, Azienda Sanitaria Universitaria Integrata, Presidio 
Ospedaliero Santa Maria della Misericordia, Piazzale S. Maria della Misericordia, 
n. 15, 33100 Udine, Italy. 
Compliance with ethical standards
Conflicts of interests
No non‑financial conflicts of interest exist for any of the authors.
Financial interest
MB serves on scientific advisory boards for Basilea, Gilead, Pfizer, Merck, and 
Astellas and has received funding for travel or speaker honoraria from Basilea, 
Gilead, Pfizer, Merck, and Astellas Pharma. LO has received research grants 
and/or speaking or consulting fees from Merck, Astellas, Pfizer, Scynexis, 
Cidara, Gilead, Meiji, and T2 biosystems. AS has served as a speaker for, con‑
sultant to, or received research support from Achaogen, Actavis, Astellas, AZ, 
Bayer, Cempra, Cidara, Entasysis, MedCo, Melinta, Merck, Paratek, Roche, Spero, 
Tetraphase, Theravamce, and Wockhordt. JFT serves on scientific advisory 
boards for Merck and Gilead and has received speaker honoraria and/or 
research grants from Merck, Astellas, and Pfizer. The other authors declare no 
conflict of interest.
Received: 11 January 2017   Accepted: 16 February 2017
References
 1. Cornely OA, Arikan‑Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti 
A, Lanternier F, Pagano L, Skiada A, Akova M et al (2014) ESCMID and 
ECMM joint clinical guidelines for the diagnosis and management of 
mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5–26
 2. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, 
Donnelly JP, Edwards JE, Erjavec Z et al (2002) Defining opportunistic 
invasive fungal infections in immunocompromised patients with cancer 
and hematopoietic stem cell transplants: an international consensus. Clin 
Infect Dis 34(1):7–14
 3. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, 
Pappas PG, Maertens J, Lortholary O, Kauffman CA et al (2008) Revised 
definitions of invasive fungal disease from the European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Coopera‑
tive Group and the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 
46(12):1813–1821
 4. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, 
Helfgott D, Holowiecki J, Stockelberg D, Goh YT et al (2007) Posaconazole 
vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
N Engl J Med 356(4):348–359
 5. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts 
R, Wible M, Goldstein BP, Schranz J et al (2007) Anidulafungin versus 
fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482
 6. Delaloye J, Calandra T (2014) Invasive candidiasis as a cause of sepsis in 
the critically ill patient. Virulence 5(1):161–169
 7. Vincent J‑L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD et al (2009) 
International study of the prevalence and outcomes of infection in inten‑
sive care units. JAMA 302(21):2323–2329
 8. Kett DH, Azoulay E, Echeverria PM, Vincent J‑L, Extended Prevalence of 
Infection in ICU Study (EPIC II) Group of Investigators (2011) Candida 
bloodstream infections in intensive care units: analysis of the extended 
prevalence of infection in intensive care unit study. Crit Care Med 
39(4):665–670
 9. Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 
373(15):1445–1456
 10. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sá M, Johnson EM 
et al (2009) Management of invasive candidiasis and candidemia in adult 
non‑neutropenic intensive care unit patients: part I. Epidemiology and 
diagnosis. Intensive Care Med 35(1):55–62
 11. Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive 
candidiasis: how nonculture diagnostics will improve understand‑
ing of disease spectrum and transform patient care. Clin Infect Dis 
56(9):1284–1292
 12. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, Diaz‑
Martin A, Luzzati R, Rosin C, Lagunes L, Trecarichi EM, Sanguinetti M, 
Posteraro B, Garnacho‑Montero J, Sartor A, Rello J, Rocca GD, Antonelli 
M, Tumbarello M (2014) A multicenter study of septic shock due to 
candidemia: outcomes and predictors of mortality. Intensive Care Med 
40:839–845
 13. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT 
(2006) Time to initiation of fluconazole therapy impacts mortality in 
patients with candidemia: a multi‑institutional study. Clin Infect Dis 
43:25–31
 14. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH (2005) Flucona‑
zole prophylaxis in critically ill surgical patients: a meta‑analysis. Crit Care 
Med 33:1928–1935
 15. Ostrosky‑Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron 
MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, 
Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes 
WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG (2014) 
MSG‑01: a randomized, double‑blind, placebo‑controlled trial of 
caspofungin prophylaxis followed by preemptive therapy for invasive 
candidiasis in high‑risk adults in the critical care setting. Clin Infect Dis 
58:1219–1226
 16. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Had‑
ley S, Slotman G, Panzer H, Biswas P, Rex JH (2008) Empirical fluconazole 
versus placebo for intensive care unit patients: a randomized trial. Ann 
Intern Med 149:83–90
 17. Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, 
Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, 
Gruson D, Paris A, Darmon M, Garrouste‑Orgeas M, Navellou JC, Foucrier 
A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, 
Wolff M, EMPIRICUS Trial Group (2016) Empirical micafungin treatment 
and survival without invasive fungal infection in adults with icu‑acquired 
sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS 
randomized clinical trial. JAMA 316:1555–1564
 18. León C, Ruiz‑Santana S, Saavedra P, Almirante B, Nolla‑Salas J, Alvarez‑
Lerma F, Garnacho‑Montero J, León MA, EPCAN Study Group (2006) A 
bedside scoring system (“Candida score”) for early antifungal treatment in 
nonneutropenic critically ill patients with Candida colonization. Crit Care 
Med 34:730–737
 19. Nucci M, Nouér SA, Esteves P, Guimarães T, Breda G, de Miranda BG, 
Queiroz‑Telles F, Colombo AL (2016) Discontinuation of empirical antifun‑
gal therapy in ICU patients using 1,3‑β‑d‑glucan. J Antimicrob Chemother 
71:2628–2633
 20. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards 
JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al (1994) A 
randomized trial comparing fluconazole with amphotericin B for the 
treatment of candidemia in patients without neutropenia. Candidemia 
Study Group and the National Institute. N Engl J Med 331:1325–1330
 21. León C, Ostrosky‑Zeichner L, Schuster M (2014) What’s new in the clini‑
cal and diagnostic management of invasive candidiasis in critically ill 
patients. Intensive Care Med 40:808–819
 22. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, 
Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, 
Hodges MR (2005) Voriconazole versus a regimen of amphotericin B 
followed by fluconazole for candidaemia in non‑neutropenic patients: a 
randomised non‑inferiority trial. Lancet 366:1435–1442
 23. Mora‑Duarte J, Betts R, Rotstein C, Colombo AL, Thompson‑Moya L, 
Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, Caspofungin 
Invasive Candidiasis Study Group (2002) Comparison of caspo‑
fungin and amphotericin B for invasive candidiasis. N Engl J Med 
347(25):2020–2029
 24. Kuse ER, Chetchotisakd P, Da Cunha CA, Ruhnke M, Barrios C, Raghunad‑
harao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, 
Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky‑
Zeichner L, Lortholary O, Koblinger S, Diekmann‑Berndt H, Cornely OA, 
Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus 
liposomal amphotericin B for candidaemia and invasive candidosis: a 
phase III randomised double‑blind trial. Lancet 369:1519–1527
 25. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez 
JA, Dupont BF, Horn DL, Ostrosky‑Zeichner L, Reboli AC, Suh B, Digumarti 
R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus 
caspofungin for treatment of candidemia and other forms of invasive 
candidiasis. Clin Infect Dis 45:883–893
 26. Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Car‑
doso T, Paiva JA, Blasco‑Navalpotro M, De Laere E, Dimopoulos G, Rello J, 
Vogelaers D, Blot SI, AspICU Study Investigators (2015) Epidemiology of 
invasive aspergillosis in critically ill patients: clinical presentation, underly‑
ing conditions, and outcomes. Crit Care 12(19):7
 27. Garnacho‑Montero J, Olaechea P, Alvarez‑Lerma F, Alvarez‑Rocha L, 
Blanquer J, Galván B, Rodriguez A, Zaragoza R, Aguado JM, Mensa J, Solé 
A, Barberán J (2013) Epidemiology, diagnosis and treatment of fungal 
respiratory infections in the critically ill patient. Rev Esp Quimioter Jun 
26(2):173–188
 28. Chun‑Yu L, Wei‑Lun L, Che‑Chia C, Hou‑Tai C, Han‑Chung H, Kuo‑chin K, 
Ning‑Hung C, Ying‑Jen C, Cheng‑Ta Y, Chung‑Chi H, Dimopoulos G (2017) 
Invasive fungal tracheobronchitis in mechanically ventilated critically ill 
patients: underlying conditions, diagnosis and outcomes. Ann Intensive 
Care 7:9.doi:10.1186/s13613‑016‑0230‑9
 29. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Gov‑
ender NP et al (2017) Simultaneous emergence of multidrug‑resistant 
Candida auris on 3 continents confirmed by whole‑genome sequencing 
and epidemiological analyses. Clin Infect Dis 64(2):134–140
 30. Marklein G, Josten M, Klanke U, Muller E, Horre R, Maier T et al (2009) 
Matrix‑assisted laser desorption ionization‑time of flight mass spec‑
trometry for fast and reliable identification of clinical yeast isolates. J Clin 
Microbiol 47(9):2912–2917
 31. Spanu T, Posteraro B, Fiori B, D’Inzeo T, Campoli S, Ruggeri A et al (2012) 
Direct maldi‑tof mass spectrometry assay of blood culture broths for 
rapid identification of Candida species causing bloodstream infections: 
an observational study in two large microbiology laboratories. J Clin 
Microbiol 50(1):176–179
 32. Ling H, Yuan Z, Shen J, Wang Z, Xu Y (2014) Accuracy of matrix‑assisted 
laser desorption ionization‑time of flight mass spectrometry for iden‑
tification of clinical pathogenic fungi: a meta‑analysis. J Clin Microbiol 
52(7):2573–2582
 33. Vella A, De Carolis E, Vaccaro L, Posteraro P, Perlin DS, Kostrzewa M et al 
(2013) Rapid antifungal susceptibility testing by matrix‑assisted laser 
desorption ionization‑time of flight mass spectrometry analysis. J Clin 
Microbiol 51(9):2964–2969
 34. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C (2012) The use 
of mannan antigen and anti‑mannan antibodies in the diagnosis of inva‑
sive candidiasis: recommendations from the Third European Conference 
on Infections in Leukemia. Crit Care 14(6):R222
 35. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richard‑
son M et al (2012) Beta‑Glucan antigenemia assay for the diagnosis of 
invasive fungal infections in patients with hematological malignancies: 
a systematic review and meta‑analysis of cohort studies from the Third 
European Conference on Infections in Leukemia (ECIL‑3). Clin Infect Dis 
54(5):633–643
 36. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A et al 
(2012) Systemic antifungal therapy in critically ill patients without inva‑
sive fungal infection. Crit Care Med 40:813–822
 37. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky‑
Zeichner L, Reboli AC, Schuster M, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel 
JD (2016) Clinical practice guideline for the management of candidiasis: 
2016 update by the Infectious Diseases Society of America. Clin Infect Dis 
62:e1–e50
 38. Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR et al (2012) 
(1,3)‑β‑d‑Glucan surveillance with preemptive anidulafungin for invasive 
candidiasis in intensive care unit patients: a randomized pilot study. PLoS 
One 7:e42282
 39. León C, Ruiz‑Santana S, Saavedra P, Castro C, Ubeda A, Loza A et al (2012) 
Value of (1 → 3) β‑d‑glucan and Candida albicans germ tube antibody 
for discriminating between Candida colonization and invasive candidi‑
asis in patients with severe abdominal conditions. Intensive Care Med 
38:1315–1325
 40. Martín‑Mazuelos E, Loza A, Castro C, Macías D, Zakariya I, Saavedra P 
et al (2015) β‑d‑glucan and Candida albicans germ tube antibody in ICU 
patients with invasive candidiasis. Intensive Care Med 41:1424–1432
 41. Prattes J, Hoenigl M, Rabensteiner J, Raggam RB, Prueller F, Zollner‑
Schwetz I, Valentin T, Hönigl K, Fruhwald S, Krause R (2014) Serum 
1,3‑beta‑d‑glucan for antifungal treatment stratification at the intensive 
care unit and the influence of surgery. Mycoses 57:679–686
 42. Posteraro B, Tumbarello M, De Pascale G, Liberto E, Vallecoccia MS, De 
Carolis E, Di Gravio V, Trecarichi EM, Sanguinetti M, Antonelli M (2016) 
(1,3)‑β‑d‑glucan‑based antifungal treatment in critically ill adults at high 
risk of candidaemia: an observational study. J Antimicrob Chemother 
71:2262–2269
 43. Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, Reis‑
man AL, Biswas P, Walsh TJ (2011) Anidulafungin compared with flucona‑
zole for treatment of candidemia and other forms of invasive candidiasis 
caused by Candida albicans: a multivariate analysis of factors associated 
with improved outcome. BMC Infect Dis 11:261
 44. Yang Q, Wang T, Xie J, Wang Y, Zheng X, Chen L et al (2016) Pharmacoki‑
netic/pharmacodynamic adequacy of echinocandins against Candida 
spp. in intensive care unit patients and general patient populations. Int J 
Antimicrob Agents 47:397–402
 45. Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M et al 
(2017) Population pharmacokinetics of micafungin in ICU patients 
with sepsis and mechanical ventilation. J Antimicrob Chemother 
72(1):181–189
 46. Brüggemann RJ, Middel‑Baars V, de Lange DW, Colbers A, Girbes AR, Pick‑
kers P, Swart EL (2017) Pharmacokinetics of anidulafungin in critically ill 
patients in the intensive care unit with suspected or proven invasive fun‑
gal infections. Antimicrob Agents Chemother. doi:10.1128/AAC.01894‑16
 47. van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis‑
Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC 
(2016) Low caspofungin exposure in patients in the intensive care unit. 
Antimicrob Agents Chemother. doi:10.1128/AAC.01582‑16
 48. Schroeder M, Simon M, Katchanov J, Wijaya C, Rohde H, Christner M, 
Laqmani A, Wichmann D, Fuhrmann V, Kluge S (2016) Does galactoman‑
nan testing increase diagnostic accuracy for IPA in the ICU? A prospective 
observational study. Crit Care 20:139
 49. Steinmann J, Buer J, Rath PM (2016) Detection of Aspergillus fumigatus in 
blood samples from critically ill patients in intensive care units by use of 
the SeptiFast assay. J Clin Microbiol 54:1918
 50. Blot S, Taccone F, Van den Abeele A, Bulpa P, Meersseman W, Brusselaers 
N, Dimopoulos G, Paiva JA, Misset B, Rello J, Vandewoude K, Vogelaers 
D, AspICU Study Investigators (2012) A clinical algorithm to diagnose 
invasive pulmonary aspergillosis in ICU patients. Am J Respir Crit Care 
Med 186(1):56–64
 51. Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of 
candidemia: a systematic review of matched cohort and case‑control 
studies. Eur J Clin Microbiol Infect Dis 25(7):419–425
 52. López‑Cortés LE, Almirante B, Cuenca‑Estrella M, Garnacho‑Montero J, 
Padilla B, Puig‑Asensio M, Ruiz‑Camps I, Rodríguez‑Baño J, members of 
the CANDIPOP Project from GEIH‑GEMICOMED (SEIMC) and REIPI (2016) 
Empirical and targeted therapy of candidemia with fluconazole versus 
echinocandins: a propensity score‑derived analysis of a population‑
based, multicentre prospective cohort. Clin Microbiol Infect 22:733
 53. Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields 
RK, Clancy CJ, Nguyen MH, Lam SW (2013) Fluconazole versus an echi‑
nocandin for Candida glabrata fungaemia: a retrospective cohort study. J 
Antimicrob Chemother 68:922–926
 54. Puig‑Asensio M, Fernández‑Ruiz M, Aguado JM, Merino P, Lora‑Pablos 
D, Guinea J, Martín‑Dávila P, Cuenca‑Estrella M, Almirante B (2016) 
Propensity score analysis of the role of initial antifungal therapy in the 
outcome of Candida glabrata bloodstream infections. Antimicrob Agents 
Chemother 60:3291–3300
 55. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, 
Pappas PG, Kullberg BJ, Mycoses Study Group (2012) Impact of treatment 
strategy on outcomes in patients with candidemia and other forms of 
invasive candidiasis: a patient‑level quantitative review of randomized 
trials. Clin Infect Dis 54:1110–1122
 56. Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin‑Hong 
P, Tobin E, Kett DH, Biswas P, Swanson R (2014) Evaluation of an early 
step‑down strategy from intravenous anidulafungin to oral azole therapy 
for the treatment of candidemia and other forms of invasive candidiasis: 
results from an open‑label trial. BMC Infect Dis 14:97
 57. Bailly S, Leroy O, Montravers P, Constantin JM, Dupont H, Guillemot 
D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Azoulay E, Timsit 
JF (2015) Antifungal de‑escalation was not associated with adverse 
outcome in critically ill patients treated for invasive candidiasis: post 
hoc analyses of the AmarCAND2 study data. Intensive Care Med 
41(11):1931–1940
 58. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE (2013) Pharmaco‑
dynamics and dose‑ response relationships of liposomal amphotericin b 
against different azole‑resistant Aspergillus fumigatus isolates in a murine 
model of disseminated aspergillosis. Antimicrob Agents Chemother 
57:1866–1871
 59. Verweij PE, Chowdhary A, Melchers WJ, Meis JF (2016) Azole resistance 
in Aspergillus fumigatus: can we retain the clinical use of mold‑active 
antifungal azoles? Clin Infect Dis 62:362–368
 60. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW 
(2009) Toxicodynamics of itraconazole: implications for therapeutic drug 
monitoring. Clin Infect Dis 49:928–930
 61. Dolton MJ, Ray JE, Chen SCA, Ng K, Pont LG, McLachlan AJ (2012) Mul‑
ticenter study of voriconazole pharmacokinetics and therapeutic drug 
monitoring. Antimicrob Agents Chemother 56:4793–4799
 62. Walsh TJ, Raad I, Patterson TF et al (2007) Treatment of invasive aspergil‑
losis with posaconazole in patients who are refractory to or intolerant 
of conventional therapy: an externally controlled trial. Clin Infect Dis 
44:2–12
 63. Hatipoglu N, Hatipoglu H (2013) Combination antifungal therapy for 
invasive fungal infections in children and adults. Expert Rev Anti Infect 
Ther 11:523–535
 64. Marr KA, Schlamm HT, Herbrecht R et al (2015) Combination antifungal 
therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 
162:81–89
 65. Martín‑Peña A, Aguilar‑Guisado M, Espigado I, Cisneros JM (2014) 
Antifungal combination therapy for invasive aspergillosis. Clin Infect Dis 
59(10):1437–1445
 66. Verweij PE, Ananda‑Rajahb M, Andes D, Arendrup MC, Brüggemann RJ, 
Chowdhary A et al (2015) International expert opinion on the manage‑
ment of infection caused by azole‑resistant Aspergillus fumigatus. Drug 
Resist Updates 21–22:30–40
 67. Denning D, Cadranel J, Beigelman‑Aubry C, Ader F, Chakrabarti A, Blot S, 
Ullman A, Dimopoulos G, Lange C, on behalf of the ESCIM and ERS (2016) 
Chronic pulmonary aspergillosis rationale and clinical guidelines for 
diagnosis and management. Eur Respir J 47(1):45–68
 68. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M 
et al (2013) Beta‑glucan antigenemia anticipates diagnosis of blood 
culture‑negative intraabdominal candidiasis. Am J Respir Crit Care Med 
188(9):1100–1109
 69. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G 
et al (2011) Early diagnosis of candidemia in intensive care unit patients 
with sepsis: a prospective comparison of (1 to >3)‑beta‑d‑glucan assay, 
Candida score, and colonization index. Crit Care 15(5):R249
 70. Angebault C, Lanternier F, Dalle F, Schrimpf C, Roupie AL, Dupuis A, 
Agathine A, Scemla A, Paubelle E, Caillot D, Neven B, Frange P, Suarez 
F, dEnfert C, Lortholary O, Bougnoux ME (2016) Prospective evaluation 
of serum β‑glucan testing in patients with probable or proven fungal 
diseases. Open Forum Infect Dis 16 3(3):ofw128. doi:10.1093/ofid/ofw128
 71. Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: 
systematic review and meta‑analysis. J Clin Microbiol 49(2):665–670
 72. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG et al 
(2012) Performance of Candida real‑time polymerase chain reaction, 
beta‑d‑glucan assay, and blood cultures in the diagnosis of invasive 
candidiasis. Clin Infect Dis 54(9):1240–1248
 73. Mylonakis E, Clancy CJ, Ostrosky‑Zeichner L, Garey KW, Alangaden 
GJ, Vazquez JA et al (2015) T2 magnetic resonance assay for the rapid 
diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 
60(6):892–899
 74. Vincent JL, Brealey D, Libert N, Abidi NE, O’Dwyer M, Zacharowski K et al 
(2015) Rapid diagnosis of infection in the critically ill, a multicenter study 
of molecular detection in bloodstream infections, pneumonia, and sterile 
site infections. Crit Care Med 43(11):2283–2291
 75. Metzgar D, Frinder MW, Rothman RE, Peterson S, Carroll KC, Zhang 
SX et al (2016) The IRIDICA BAC BSI assay: rapid, sensitive and culture‑
independent identification of bacteria and Candida in blood. PLoS One 
11(7):e0158186
 76. Rodríguez‑Sánchez B, Sánchez‑Carrillo C, Ruiz A, Marín M, Cercenado E, 
Rodríguez‑Créixems M, Bouza E (2014) Direct identification of pathogens 
from positive blood cultures using matrix‑assisted laser desorption‑
ionization time‑of‑flight mass spectrometry. Clin Microbiol Infect 
20:O421–O427
 77. Idelevich EA, Grünastel B, Becker K (2016) Rapid detection and identifica‑
tion of candidemia by direct blood culturing on solid medium using 
lysis‑centrifugation method combined with MALDI‑TOF MS. J Clin Micro‑
biol 55(1):97–100
 78. Da Silva RM Jr, Da Silva Neto JR, Santos CS, Frickmann H, Poppert S, Cruz 
KS, Koshikene D, De Souza JV (2015) Evaluation of fluorescence in situ 
hybridisation (FISH) for the detection of fungi directly from blood cultures 
and cerebrospinal fluid from patients with suspected invasive mycoses. 
Ann Clin Microbiol Antimicrob 14:6
 79. Mylonakis E, Clancy CJ, Ostrosky‑Zeichner L, Garey KW, Alangaden GJ, 
Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, 
Zacharioudakis IM, Kontoyiannis DP, Pappas PG (2015) T2 magnetic 
resonance assay for the rapid diagnosis of candidemia in whole blood: a 
clinical trial. Clin Infect Dis 60:892–899
 80. Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, 
Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr 
T, Wallis SC, Dimopoulos G, DALI Study authors (2015) Pharmacokinetic 
variability and exposures of fluconazole, anidulafungin, and caspo‑
fungin in intensive care unit patients: data from multinational Defining 
Antibiotic Levels in Intensive care unit (DALI) patients study. Crit Care 
19:33
 81. Lin CY, Liu WL, Chang CC, Chang HT, Hu HC, Kao KC, Chen NH, Chen YJ, 
Yang CT, Huang CC, Dimopoulos G (2017). Invasive fungal tracheobron‑
chitis in mechanically ventilated critically ill patients: underlying condi‑
tions, diagnosis, and outcomes. Ann Intensive Care 7(1):9. doi:10.1186/
s13613‑016‑0230‑9
 82. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock 
attributed to Candida infection: importance of empiric therapy and 
source control. Clin Infect Dis 54(1):1739–1746
 83. Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields 
RK, Clancy CJ, Nguyen MH, Lam SW (2013) Fluconazole versus an echi‑
nocandin for Candida glabrata fungaemia: a retrospective cohort study. J 
Antimicrob Chemother 68:922–926
 84. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho‑Montero J, 
Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P, Rocca GD, Roilides 
E, Sganga G, Walsh TJ, Tascini C, Tumbarello M, Menichetti F, Righi E, 
Eckmann C, Viscoli C, Shorr AF, Leroy O, Petrikos G, De Rosa FG (2013) A 
research agenda on the management of intra‑abdominal candidiasis: 
results from a consensus of multinational experts. Intensive Care Med 
39(12):2092–2106
 85. Plantinga TS, Johnson MD, Scott WK, van de Vosse E, Velez Edwards DR, 
Smith PB, Alexander BD, Yang JC, Kremer D, Laird GM, Oosting M, Joosten 
LA, van der Meer JW, van Dissel JT, Walsh TJ, Perfect JR, Kullberg BJ, Netea 
MG (2012) Toll‑like receptor 1 polymorphisms increase susceptibility to 
candidemia. J Infect Dis 205:934–943
 86. Kumar V, Cheng SC, Johnson MD, Smeekens SP, Wojtowicz A, Giamarellos‑
Bourboulis E, Karjalainen J, Franke L, Withoff S, Plantinga TS, van de 
Veerdonk FL, van der Meer JW, Joosten LA, Sokol H, Bauer H, Herrmann 
BG, Bochud PY, Marchetti O, Perfect JR, Xavier RJ, Kullberg BJ, Wijmenga C, 
Netea MG (2014) Immunochip SNP array identifies novel genetic variants 
conferring susceptibility to candidaemia. Nat Commun 5:4675
 87. Kullberg BJ, van de Veerdonk F, Netea MG (2014) Immunotherapy: a 
potential adjunctive treatment for fungal infection. Curr Opin Infect Dis 
27(6):511–516
 88. Boff C, Zoppas BC, Aquino VR, Kuplich NM, Miron D, Pasqualotto AC 
(2013) The indoor air as a potential determinant of the frequency of 
invasive aspergillosis in the intensive care. Mycoses 56(5):527–531
